Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study of Nivolumab in Combination With Ipilimumab (Part 1); and Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)
Brief Summary: The purpose of part 1 of this study is to determine the objective response rate (ORR) in stage IV NSCLC subjects treated with nivolumab in combination with ipilimumab as first line therapy.

The purpose of part 2 of this study is to determine the safety and tolerability of nivolumab and ipilimumab combined with a short course of chemotherapy in first line stage IV NSCLC.


Options:
A: Arm Label: pemetrexed + cisplatin followed by pemetrexed; Type: EXPERIMENTAL; Interventions: Drug: Pemetrexed, Drug: Cisplatin, Other: Best Supportive Care | Arm Label: pemetrexed + cisplatin followed by placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pemetrexed, Drug: Cisplatin, Drug: Placebo, Other: Best Supportive Care | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): pemetrexed + cisplatin followed by pemetrexed, pemetrexed + cisplatin followed by placebo | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): pemetrexed + cisplatin followed by pemetrexed, pemetrexed + cisplatin followed by placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): pemetrexed + cisplatin followed by placebo | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): pemetrexed + cisplatin followed by pemetrexed | Intervention Type: OTHER; Name: Best Supportive Care; Assigned to Arm(s): pemetrexed + cisplatin followed by pemetrexed, pemetrexed + cisplatin followed by placebo
B: Arm Label: Nivolumab+Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Nivolumab+Ipilimumab + 2 cycles Platinum Doublet Chemotherapy; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab, Drug: Platinum Doublet Chemotherapy | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Nivolumab+Ipilimumab, Nivolumab+Ipilimumab + 2 cycles Platinum Doublet Chemotherapy | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Nivolumab+Ipilimumab, Nivolumab+Ipilimumab + 2 cycles Platinum Doublet Chemotherapy | Intervention Type: DRUG; Name: Platinum Doublet Chemotherapy; Assigned to Arm(s): Nivolumab+Ipilimumab + 2 cycles Platinum Doublet Chemotherapy
C: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm B: Docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: Docetaxel
D: Arm Label: Dose Escalation; Type: EXPERIMENTAL; Interventions: Drug: MEDI4736, Drug: Tremelimumab | Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: MEDI4736, Drug: Tremelimumab | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: MEDI4736, Drug: tremelimumab | Arm Label: Arm C; Type: EXPERIMENTAL; Interventions: Drug: MEDI4736, Drug: tremelimumab | Intervention Type: DRUG; Name: MEDI4736; Assigned to Arm(s): Arm A, Arm B, Arm C, Dose Escalation | Intervention Type: DRUG; Name: Tremelimumab; Assigned to Arm(s): Arm A, Dose Escalation | Intervention Type: DRUG; Name: tremelimumab; Assigned to Arm(s): Arm B, Arm C

Answer: B